Comparative Pharmacology
Head-to-head clinical analysis: SODIUM AMINOSALICYLATE versus SODIUM P A S.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SODIUM AMINOSALICYLATE versus SODIUM P A S.
SODIUM AMINOSALICYLATE vs SODIUM P.A.S.
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sodium aminosalicylate inhibits folic acid synthesis in Mycobacterium tuberculosis by competing with para-aminobenzoic acid (PABA) for the enzyme dihydropteroate synthase, thereby blocking bacterial growth.
Sodium P.A.S. (para-aminosalicylate) inhibits folic acid synthesis in Mycobacterium tuberculosis by competing with para-aminobenzoic acid, thereby suppressing bacterial growth.
4 g orally three times daily (total daily dose 12 g) for tuberculosis treatment. Also available as 10 g in 250 mL for intravenous infusion over 5-6 hours, typically once daily.
4 g orally three times daily (total 12 g/day). For intravenous administration, 4 g (10 mL of 40% solution) diluted in 250 mL of 5% dextrose or normal saline infused over 2-3 hours three times daily.
None Documented
None Documented
0.75-1.5 hours (parent drug); prolongs to 4-6 hours in renal impairment or with probenecid coadministration. Rapid acetylation phenotype reduces half-life by ~30%.
0.5–1 hour (normal renal function); prolonged to ≥10 hours in renal impairment (requires dose adjustment).
Renal: >80% as metabolites (acetylated and free), with 50-60% as N-acetyl-4-aminosalicylic acid; biliary/fecal: <1%.
Primarily renal (80-90% as unchanged drug) via glomerular filtration and tubular secretion; biliary/fecal ≤10%.
Category C
Category C
Antitubercular Agent
Antitubercular Agent